Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Xenetic Biosciences, Inc.

XBIO

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.48 – $1.74
Volume 2,486
Market cap $3M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.49M
Price / earnings
—
Price / book
0.79×
Price / sales
1.59×
EV / sales
-1.06×
EV / EBITDA
0.5×

Profitability

Earnings per share
-$1.56
Return on assets
-57.94%
Return on equity
-82.94%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.15×
Quick ratio
3.15×
Cash ratio
3.05×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$2.32M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XBIO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$725.26K$660.6K$806.92K$0$1.03M$589.9K$593.26K$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$725.26K$660.6K$806.92K$0$1.03M$589.9K$593.26K$0
Selling, general and administrative$1.94M$1.08M$647.6K$615.91K$815.21K$657.75K$656.64K$705.71K
Research and development$520.66K$552.01K$661.44K$773.42K$756.48K$656.56K$879.03K$1.04M
Total operating expenses$2.46M$1.63M$1.31M$1.39M$1.57M$1.31M$1.54M$1.75M
Operating income-$1.74M-$971.69K-$502.12K-$1.39M-$544.73K-$724.41K-$942.41K-$1.75M
Interest expense$0$0$0-$104.21K$0$0$0-$197.99K
Income before taxes-$1.7M-$929.7K-$456.38K-$579.08K-$509.94K-$688.7K-$903.14K-$1.05M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.7M-$929.7K-$456.38K-$579.08K-$509.94K-$688.7K-$903.14K-$1.05M
Net income attributable to common shareholders-$1.7M-$929.7K-$456.38K-$579.08K-$509.94K-$688.7K-$903.14K-$1.05M
EBITDA-$1.74M-$971.69K-$502.12K-$1.39M-$544.73K-$724.41K-$942.41K-$1.75M
Basic earnings per share-$0.72-$0.41-$0.20-$0.27-$0.33-$0.45-$0.59-$0.68
Diluted earnings per share-$0.72-$0.41-$0.20-$0.27-$0.33-$0.45-$0.59-$0.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences

HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ: XBIO) from Buy to Neutral, citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic announced a one-for-ten reverse stock split, the second ...Full story available on Benzinga.com

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 15, 20231-for-10reverse split
Jun 25, 20191-for-12reverse split
Jun 1, 20161-for-33reverse split
Mar 1, 201310-for-1forward split